Moreover, another research unveiled that p38 MAPK confers intrinsic resistance to EGFR TKIs, lapatinib and gefitinib, in K-Ras mutant colon cancer cell lines, by concurrent stimulation of EGFR gene transcription and protein dephosphorylation [37]. This evidence concerns the gene KRAS and colonic neoplasm.